Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 3/20 | 0.56 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.56 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.56 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.56 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.56 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 11/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14870541 | 0.92 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8023232 | 0.82 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14870539 | 0.82 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8021550 | 0.80 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12891958 | 0.77 | HSD11B1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12891767 | 0.76 | HSD11B1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12891770 | 0.76 | HSD11B1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13848502 | 0.75 | PIK3CD (0.32) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12891947 | 0.75 | HSD11B1 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2873080 | 0.75 | HSD11B1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130095068-A1 | AGENT FOR TREATING HCV INFECTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-20130095068-A1 | AGENT FOR TREATING HCV INFECTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130095068-A1 | AGENT FOR TREATING HCV INFECTION | EIF2AK2, IRF3, IFNAR1 | PSEN1 4882/4885PSEN2 4883/4885APH1B 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.